Abstract

Cambodia's Ministry of Health and the Department of Drugs and Food have been actively working to reduce the amount of poor quality medicines circulating in the pharmaceutical sector since fake mefloquine and artesunate were first found in 1998. From 2005-2012, legal private sector facilities and illegal outlets in twelve Cambodian provinces were targeted for routine surveillance of medicine quality through sample collection and testing of various anti-infective medicines, the majority of which were anti-malarials and anti-biotics. The Medicine Quality Monitoring program samples from the field were analyzed through a three level approach including field and advanced laboratory testing. 4,381 medicines were collected and tested from 2005-2012; 106 have failed quality testing resulting in an overall failure rate of 2.4%. 28 of the failed samples (26.4%) were counterfeit. The most commonly found counterfeit medicines were chloroquine, artesunate, mefloquine, ampicillin and penicillin. Cambodia has closed over 99% of illegal pharmacy outlets through the Inter-Ministerial Committee to Fight against Counterfeit & Substandard Medicines (IMC) by the end of November 2011. In the past, a lack of resources as well as coordination among the various ministries was identified as a major barrier in combating the presence of poor quality medicines. With financial support from USAID, PMI, and other donors, paired with the technical support from the U.S. Pharmacopeial Convention Promoting the Quality of Medicines program, the IMC developed an action plan to significantly reduce the number of substandard and counterfeit medicines. Based on the data shown, the plan has been successful in reducing the failure rates of samples collected in Cambodia from a high of 7.4% in 2006 to a low of 0.7% in 2011. Continued efforts to monitor and actively ensure the quality of medicines in Cambodia will be required to maintain these low rates; sustainability of these efforts is critical.

Highlights

  • As one of the first locations in South-East (SE) Asia to identify counterfeit malaria medicines, Cambodia has been working to reduce poor quality medicines since counterfeit mefloquine and artesunate were first noticed in 1998 [1]

  • The data presented in this paper identifies the impact on the prevalence of poor quality medicines, which has occurred prior to, and following the initiation of the containment project

  • The highest rate of medicines that failed quality testing was in Phnom Penh, where there is the largest number of pharmacy outlets and market for pharmaceuticals in Cambodia

Read more

Summary

Introduction

As one of the first locations in South-East (SE) Asia to identify counterfeit malaria medicines, Cambodia has been working to reduce poor quality medicines since counterfeit mefloquine and artesunate were first noticed in 1998 [1]. The use of poor quality medicines may lead to treatment failure, increased morbidity and mortality, and the development of drug resistance [2,3]. The border area between Cambodia and Thailand has a history of malaria parasites resistant to a number of therapeutic agents [2,3,4,5]. Beginning in the 1960s, malaria in this region first became resistant to chloroquine followed by sulfadoxine-pyrimethamine [6,7]. These resistant parasites spread to the rest of the world, rendering these key chemotherapeutic agents essentially ineffective in treating malaria [8]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call